ANX-005 is under clinical development by Annexon and currently in Phase II for Acquired (Autoimmune) Hemolytic Anemia. According to GlobalData, Phase II drugs for Acquired (Autoimmune) Hemolytic Anemia have a 53% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how ANX-005’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

ANX-005 overview

ANX-005 is under development for the treatment and acute antibody-mediated autoimmune disease such as Guillain-Barre syndrome, amyotrophic lateral sclerosis, warm autoimmune hemolytic anemia, Huntington disease and multifocal motor neuropathy (MMN). It is administered as intravenous infusion. The drug candidate is a humanized monoclonal antibody that inhibits early components of the classical complement cascade. It is based on composite human antibody technology. The drug candidate was also under development for the treatment of Alzheimer's disease.

Annexon overview

Annexon is a developer of therapeutic products and pathway inhibitors for the treatment of neurological disorders. The company develops treatments for Huntington’s disease and Alzheimer’s disease by targeting complement-mediated neurodegeneration. Its lead drug candidates include ANX005 and ANX007, which are potent inhibitory antibodies against C1q, an initiating molecule of the classical complement cascade. The compay also develops ANX105, for the treatment of neurodegenerative disorders. It develops therapeutic products to protect against synapse loss and inflammatory nerve damage in brain and retinal cells. Annexon is headquartered in South San Francisco, California, the US.

For a complete picture of ANX-005’s drug-specific PTSR and LoA scores, buy the report here.

This content was updated on 2 September 2023

Premium Insights


The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.